Affimed begins subject dosing in acute myeloid leukaemia therapy trial

Affimed has dosed the first participant in the first-in-human Phase I trial of AFM28 to treat CD123-positive relapsed/refractory (r/r) acute myeloid leukaemia (AML) patients.

The open label, multicentre, dose escalation Phase I AFM28-101 trial has been designed for evaluating pharmacodynamics, pharmacokinetics, tolerability, and safety of AFM28 monotherapy in the indicated patients.